<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727907</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-033-2</org_study_id>
    <nct_id>NCT02727907</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis</brief_title>
  <official_title>International, Multicenter, Double-blinded, Placebo-controlled, Randomized Study of the Efficacy and Safety of Drugs BCD-033 and Rebif for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design is double-blind, randomized, placebo-controlled study in 3 parallel groups with
      the use of active comparator and placebo. Total duration of therapy of about 2 years. Study
      hypothesis is equivalence of efficacy and safety of the investigational drug BCD-033 original
      drug Rebif®.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Combined Unique Active Lesions</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of Combined Unique Active Lesions (CUA) -- the number of new MRI contrast uptake lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice) after 48 weeks blinded application of interferon-β1а (BCD-033 and Rebif®) in full dose (44 mcg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual relapse rate</measure>
    <time_frame>16, 52, 96 weeks</time_frame>
    <description>Annual relapse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects without confirmed relapse</measure>
    <time_frame>16, 52, 96 weeks</time_frame>
    <description>proportion of subjects without confirmed relapse in &quot;per protocol&quot; population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free time</measure>
    <time_frame>16, 52, 96 weeks</time_frame>
    <description>Relapse free time in &quot;per protocol&quot; population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Combined Unique Active Lesions</measure>
    <time_frame>16, 96 weeks</time_frame>
    <description>CUA (the number of new MRI contrast uptake lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse risk</measure>
    <time_frame>16, 52, 96 weeks</time_frame>
    <description>Relapse risk in &quot;per protocol&quot; population</description>
  </secondary_outcome>
  <other_outcome>
    <measure>sustained disability progression risk</measure>
    <time_frame>52, 96 weeks</time_frame>
    <description>sustained disability progression risk is evaluated according Expanded Disability Status Scale score</description>
  </other_outcome>
  <other_outcome>
    <measure>Multiple Sclerosis Functional Composite (MSFC) score</measure>
    <time_frame>52, 96 weeks</time_frame>
    <description>progression, evaluated according MSFC score</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events/Serious adverse events</measure>
    <time_frame>16, 52, 92 weeks</time_frame>
    <description>quantity and grade of all AE/SAE is calculated in subjects, who received at least one dose of study drug</description>
  </other_outcome>
  <other_outcome>
    <measure>Severe adverse events frequency</measure>
    <time_frame>16, 52, 92 weeks</time_frame>
    <description>AE/SAE grade 3-4 (CTCAE 4.03)is calculated in subjects, who received at least one dose of study drug</description>
  </other_outcome>
  <other_outcome>
    <measure>Withdrawal</measure>
    <time_frame>16, 52, 92 weeks</time_frame>
    <description>quantity of withdrawals due to AE/SAE is calculated in subjects, who received at least one dose of study drug</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>16, 52, 92 weeks</time_frame>
    <description>proportion of binding- &amp; neutralising- antibodies positive patients</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>BCD-033</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rebif</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks, followed by 48 weeks of open-label BCD-033 usage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for 48 weeks, followed by 72 weeks of open-label BCD-033 usage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCD-033 (interferon beta 1a)</intervention_name>
    <description>Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks</description>
    <arm_group_label>BCD-033</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebif (interferon beta 1a)</intervention_name>
    <description>Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks</description>
    <arm_group_label>Rebif</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-55

          2. Patients of both genders with Multiple Sclerosis (McDonald criteria 2010)

          3. No relapses 28 days before randomisation

          4. Expanded Disability Status Scale score 0-5,5

        Exclusion Criteria

          1. Primary or secondary progression of Multiple Sclerosis

          2. Expanded Disability Status Scale score more then 5,5

          3. Severe depression, suicide ideas and/or attempts

          4. Systemic corticosteroid application in 30 days before randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scientific neurology center, RAS</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.biocad.ru</url>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>July 22, 2016</last_update_submitted>
  <last_update_submitted_qc>July 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

